IGF-LR3Interpret the evidence
Why an amyloid plaque change did not establish cognitive improvement
2 numbered sourcesSource years 1992, 2024
Short amino-acid chains connected by peptide bonds can carry signals, and longer relatives can alter cellular responses. IGF-LR3 is an engineered form of insulin-like growth factor 1 with a 13-residue extension and an arginine substitution. In a mouse study, researchers asked whether exposing the brain to this variant changed amyloid deposits and performance on behavioral tests. [1, 2]
No recent primary study repeating this exact question was identified. The older paper first appeared online in November 2024. Investigators compared the LR3 form and a control solution in male mice carrying a combination of genetic changes that produces amyloid plaques, and included mice without those changes for comparison. They measured different forms of amyloid in brain regions and used behavioral tasks to examine aspects of cognition. [1]
The authors reported changes in the makeup of amyloid plaques in the cerebral cortex. Larger, filament-like deposits became less prominent relative to a smaller form, and some soluble amyloid species were reduced. The effects were less pronounced in the hippocampus. The researchers did not find preservation of cognitive performance in the treated mice. The laboratory could detect a change in a tissue marker without observing the functional outcome it was looking for. [1]
The experiment directly tested the engineered LR3 molecule in a particular mouse model. It leaves open what caused the difference between the tissue and behavioral results and whether other models would respond similarly. The results provide no evidence that the variant prevents or treats cognitive decline in people. A change in plaque composition is distinct from a change in behavior and would need its own clinical interpretation. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Engel MG et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's Disease (publication 2024-11-29). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
- 2.Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology (publication 1992-06). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
